Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $6.4000 (-1.69%) ($6.1500 - $6.7200) on Wed. Dec. 4, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.7% (three month average) | RSI | 72 | Latest Price | $6.4000(-1.69%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 3% a day on average for past five trading days. | Weekly Trend | ADMS advances 5.8% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) IGOV(12%) UNG(9%) BWX(7%) SLV(5%) VIXM(4%) | Factors Impacting ADMS price | ADMS will decline at least -2.85% in a week (0% probabilities). URA(-22%) BLOK(-16%) XLE(-15%) XLK(-14%) ACES(-14%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.85% (StdDev 5.7%) | Hourly BBV | 0 () | Intraday Trend | 2.9% | | | |
|
5 Day Moving Average | $6.13(4.4%) | 10 Day Moving Average | $5.82(9.97%) | 20 Day Moving Average | $5.59(14.49%) | To recent high | -14.2% | To recent low | 25% | Market Cap | $181m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |